Renal & Urology News7d
Novel Drug Shows Early Efficacy in Treating Pruritus
Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...
Itchy Skin at Night Could Be a Sign That It's Time to Change Your Sheets
Nighttime itch can be annoying and even worrying. Here, 5 possible reasons you're itchy at night, as well as ...
What's Going On With Tharimmune Shares Wednesday?
Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive ...
Joplin Globe8d
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal ...
Business Insider6d
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
"The recent regulatory feedback from the EMA builds on the previous positive interactions with the FDA while providing a roadmap for TH104 for chronic pruritus in PBC, which continues to be a ...